Pelthos Q2 FY26 net loss narrows to $23.42 million; net product revenue climbs 45% to $15.4 million - PTHS News | RalliesPelthos Q2 FY26 net loss narrows to $23.42 million; net product revenue climbs 45% to $15.4 million
P
PTHS• Quarterly results
- Pelthos posted a GAAP net loss of $23.4 million, narrowing from $25.1 million in the prior quarter.
- Net product revenue rose 45% quarter-over-quarter to $15.4 million, driven by Zelsuvmi.
- Adjusted EBITDA loss narrowed to $5.7 million under non-GAAP measures, from $8 million in the prior quarter.
Commercialization timeline
- The company is targeting Xepi commercialization in Q1 2027 and Xeglyze in Q3 2027.
Product dispensing and prescriber trends
- Zelsuvmi units dispensed climbed 48% quarter-over-quarter to 11,925, written by 4,571 unique prescribers.
- Management cited July dispensing of more than 4,200 units.
CRWV
•
